Eur Rev Med Pharmacol Sci 2017; 21 (13): 3075-3082

Methionine synthase A2756G polymorphism and lymphoma risk: a meta-analysis

S.-J. Guo, S.-C. Luo, W.-Y. Liu, Q.-N. Zuo, X.-H. Li

The Affiliation Hospital of University of Electronic Science and Technology of China, Internal Medicine of Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, Sichuan, China. shujinguo@126.com


OBJECTIVE: The association between methionine synthase (MS) A2756G polymorphism and lymphoma risk was studied with conflicting results. The present meta-analysis aimed to investigate the overall association between MS A2756G polymorphism and lymphoma risk.

MATERIALS AND METHODS: We searched PubMed and Embase databases until March 30, 2017, for articles that assessed the association between MS A2756G polymorphism and lymphoma risk. Statistical analyses were performed using the Revman 5.0 software.

RESULTS: A total of 14 articles involving 4,156 cases and 6,407 controls were included in this meta-analysis. Combined analysis revealed no association between this polymorphism and lymphoma susceptibility (OR = 0.92, 95% CI: 0.74-1.16, p = 0.50 for GG vs. GA+AA). Subgroup analysis by ethnicity showed decreased lymphoma risk with the MS A2756G gene polymorphism among Caucasians in GG+GA vs. AA and G vs. A models, but not among Asians. Subgroup analysis by disease type suggested that GG homozygous and G alleles were not associated with risks of non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), the subtype of NHL including the diffuse large B-cell lymphoma and follicular lymphoma.

CONCLUSIONS: The results in this meta-analysis suggest no association between the MS A2756G polymorphism and lymphoma risk; however, the GG homozygous and G alleles could decrease the lymphoma risk in Caucasians.

Free PDF Download

To cite this article

S.-J. Guo, S.-C. Luo, W.-Y. Liu, Q.-N. Zuo, X.-H. Li
Methionine synthase A2756G polymorphism and lymphoma risk: a meta-analysis

Eur Rev Med Pharmacol Sci
Year: 2017
Vol. 21 - N. 13
Pages: 3075-3082